Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services, reviews USP 795 & 800 revisions and impacts on compounding pharmacies in the first of a four-part series.

Matt Martin points out the most significant change in the newly proposed version of USP Chapter 797 as well as the cascading effects it has on the guidelines. He also explains the process for the proposed version to become official and what compounding pharmacies and other stakeholders should do about it now.

PCCA's Director of Formulation Development Melissa Merrell Rhoads, PharmD, provides part one in a set of posts detailing the upcoming changes to our formulas based upon the new USP guidelines.

Dylan Herr, RA/QA Development Manager at Eagle, understands that the revised USP <797> chapter for sterile compounding makes significant revisions to the old chapter. In this latest article, Dyan is happy to provide you with an overview of those changes and strategies for implementing them.

The only thing that stays the same is that everything changes. This is true even when it comes to nonsterile compounding and USP <795>. PCCA Clinical Compounding Pharmacist Matt Martin, PharmD, addresses notable changes of the new USP guidelines and provides some considerations regarding implementation.